Bayer's Next Chapter Is Still on Hold—Except in Pharma

An upgraded outlook, a first-in-class approval and a near-final glyphosate settlement let management argue the turnaround is real; the spin-off question and a EUR 3 billion cash burn say the market may wait for proof.

BAYN.DE · Earnings Call · 2026-11-03

The upgrade is real—but it is a Pharma upgrade

Bayer's third-quarter message was discipline with a capital D: the group is still messy, but management can point to a firmer operating base and a higher outlook. Sales grew 3% organically and adjusted EBITDA 7% year to date; core EPS came in at EUR 3.97. The company raised full-year adjusted EBITDA to EUR 9.8bn-EUR 10.3bn, free cash flow to minus EUR 1.5bn-minus EUR 0.5bn and now expects year-end net financial debt of EUR 28bn-EUR 29bn. Bill Anderson framed it as “we're on track to deliver our commitments with a strong operational performance, and we're even upgrading our outlook in several areas” — William Anderson, CEO or Senior Executive · 2026-11-03. That is a real change from the defensive tone of the last two years, but the mix matters. Pharma is the engine: 2% organic growth year to date, a 26.8% EBITDA margin, Nubeqa up 60% and Kerendia up 76%. The first approval of asundexian as a Factor XIa inhibitor in China is a genuine pipeline milestone, not a guidance tweak. The growth trajectory in Pharma has turned; the question is whether it can broaden beyond two products. Crop Science is less clean. The division is growing about 3.5% with a 24.6% EBITDA margin, but that is a Seeds and Traits story. Core Crop protection is down on portfolio exits, regulatory impacts and generic pressure, compounded by a historic European drought and a strong El Nino. Crop Science is doing what it promised on cost and innovation, but the core protection market is still a drag. Consumer Health grew 2% with a 22.9% margin; Dermatology and Digestive Health are working, while Allergy and cold is down on a weaker season and North America remains challenging. Consumer Health is not yet a growth engine. The Latin America season is off to a strong start, but one region cannot carry the group.

The cash flow still belongs to the lawyers

The uncomfortable part of the quarter is that the upgraded operating story sits on top of a still-ugly cash picture. Judith Hartmann reported “negative EUR 3 billion for the first 9 months of the year, largely driven by EUR 3.7 billion of litigation-related payments” — Judith Hartmann, CFO or Finance Executive · 2026-11-03. Net debt rose to EUR 31.1bn, though that was better than both the prior-year and prior-quarter comparisons after the EUR 3bn Apollo equity investment closed. The market will not fully re-rate the operating business until the glyphosate tail is contained. Management knows it. The proposed class settlement has had its final approval hearing and is awaiting the judge's ruling. Anderson said it could be “any week now” — William Anderson, CEO or Senior Executive · 2026-11-03 and that Bayer still expects it before Christmas. The legal narrative has shifted in a subtle way. In August, the final approval hearing was scheduled for Aug. 19; this quarter, management described the hearing as having occurred in September and said it is waiting for the ruling. The company also won the Aretino case 12-0, the first trial after the Supreme Court struck down the failure-to-warn theory. That matters because it gives plaintiffs' lawyers a reason to reconsider. Anderson said opt-outs are trying to get back into the class, which is a good sign for significant containment. But PCBs remain a separate, episodic liability with reserves that are hard to judge. The class settlement is the near-term binary; it is not the end of all litigation.

The last thing we're going to do is stop all that, say, Hey, put all that on hold for 2 to 3 years while we do some sort of spin-off or breakout. So we're not doing that today.
William Anderson, CEO or Senior Executive · 2026-11-03

AI, DSO and the spin-off non-answer

The freshest language in this call was not about drugs or seeds. It was about individual contributors, use AI and Dynamic Shared Ownership. Anderson has moved from defending the operating model to selling it as an AI advantage. The numbers are striking: managers down from 16,000 to 4,500, total employees around 88,000, roughly 83,000 individual contributors, and 95% of decision-making pushed to them. The argument is that AI adoption is bottom-up, not a management committee. It is a genuinely company-specific story, even if every large company is talking about AI. The risk is that it sounds like another restructuring slogan if the financials do not follow. The job-cut number also has not moved much. Current management says Bayer is down about 14,000 jobs from its 2023 peak, while in March the figure was already “about 14,000 job reductions since we began implementing the new system” — William Anderson, CEO or Chairman (Board member leading the call) · 2026-03-04. The company has added AI and software roles inside that number, so the gross reduction is larger, but the net number is not fresh. That is why the AI/DSO narrative needs proof in margins and cash, not just headcount. On business development, Anderson was unusually blunt that “between 80% and 90% of late-stage deals end up being negative NPV” — William Anderson, CEO or Senior Executive · 2026-11-03, so Bayer will keep hunting early-stage molecules rather than buy its way into growth. That is a clearer capital-allocation message than the market has heard from Bayer in years, and it makes late stage deals the exception rather than the plan. The spin-off question is the tell. Antje Honing of Rheinische Post asked directly whether the end of the litigation wave puts Consumer Health or a breakup back on the table. Anderson said no, not today, and repeated that management will not pause the operating momentum for a two-to-three-year structural exercise. In August, he had used almost the same framing: “we're not going to allow it to be a distraction for us while we've got this momentum” — William Anderson, CEO or Senior Executive · 2026-08-04. The repetition is the signal. Bayer is still a three-division conglomerate with a litigation overhang, and management wants the market to value the operating turnaround first.

What would make this a new chapter

The bull case is now simple: Pharma growth plus settlement approval plus AI-driven productivity can finally let Bayer be valued as an operating company rather than a lawsuit with a dividend. The bear case is equally simple: free cash flow is still negative, net debt is still above EUR 30bn, Crop protection is still shrinking, and the settlement is not final. The launch strategy for asundexian was already flagged in August, when Anderson said “we certainly have every intention of launching in every country possible” — William Anderson, CEO or Senior Executive · 2026-08-04; the difference now is that approval is real and pricing is the constraint. The drug pricing debate around asundexian and U.S. most-favored-nation policy adds another layer of uncertainty to the one asset that could change the Pharma story. The company's own cash generation target is the proof point to watch. Until the judge rules and cash flow turns, this remains a show-me story: better operationally, but not yet de-risked. That may be enough. But the market has heard the phrase next chapter before, and the last two calls were also about containment, focus and momentum. The difference this time is that the outlook is higher and the pipeline has a real approval. The missing piece is still the same: the legal tail and the cash flow. Until those clear, Bayer is improving, not transformed.